In Vivo CAR T-Cell Therapy Concept

Umoja Biopharma aims to revolutionize CAR T-cell therapy by developing in vivo treatments that reprogram the immune system to target and destroy cancer cells directly within the body. This approach contrasts with traditional methods requiring time-consuming and expensive ex vivo processes, where T-cells are extracted, modified, and reinfused. By delivering gene therapy in a single session, Umoja hopes to simplify treatment processes, reduce costs, and make these life-saving therapies more accessible to patients. Specifically, the company seeks to address the challenges of current CAR T therapies by allowing patients to quickly receive effective treatments without the need for extensive hospitalizations.